MedImpact Healthcare Systems Expands Scope of Specialty Pharmacy Solutions

SAN DIEGO--(BUSINESS WIRE)--

As the cost and utilization of biotech drugs rise, MedImpact Healthcare Systems, Inc. is expanding its specialty pharmacy services to include high-touch programs that promote individualized patient care with clinical support tools for meaningful population management.

Optimization of care results from astute population assessment, treatment monitoring and care coordination to ensure each patient gets the right drug at the right time in the ideal setting to preserve health status, said David DAltorio, PharmD, MedImpact senior vice president of health services. Our new ChoiceSpecialty disease-specific programs for hemophilia and multiple sclerosis are joint efforts with best-in-class specialty pharmacy organizations to enhance disease-specific treatment with data collection and analysis at a population level. Reporting aggregated data provides a feedback loop for opportunities to integrate specialty drug management into the medical benefit and leverage plan sponsor investments in health care.

MedImpacts ChoiceSpecialty Hemophilia Program focuses on identifying opportunities to reduce the patients required amount of clotting factor thereby lowering costs. The program leverages a high-touch model that includes education of the patient in the community. Knowledge of how to live with hemophilia prevents inappropriate clotting factor administration and unnecessary emergency room visits or hospitalizations to treat bleeding episodes. The program includes MedImpact oversight with monitoring for waste, promotion of quality and service delivery, and reporting of insights into the costs of care.

We are excited to co-develop this program with MedImpact, said Eric Hill, co-founder and vice president of BioRx. Our agreement forms a true best-in-class partnership that is bringing a unique offering to MedImpacts clients while focusing on the high-touch needs of members with bleeding disorders.

The ChoiceSpecialty Multiple Sclerosis Program is designed to provide clinical management support and an understanding of population disability status and its impact on medical cost. The MS program has been designed to capitalize on our industrys best practices for data capture, clinical interventions and advanced reporting. The program includes gathering of key clinical indicator data, ongoing monitoring and care management, and clinical care coordination with patients and providers. Longitudinal reporting on disease impact is shared with providers and payers to enhance quality at patient, provider and population levels.

The US Bioservices team is proud of the new and innovative patient care tools and reports that are part of the ChoiceSpecialty Multiple Sclerosis Program, said Craig Miller, president of US Bioservices. MedImpact and US Bioservices have formulated a modified functional disability scoring methodology to supplement the comprehensive assessment conducted by the patients physician. We use this proprietary tool to help assess patients and track their response to MS therapies.

These new disease-focused programs supplement MedImpacts long-standing ChoiceSpecialty dispensing channel management program launched in 2008.

About MedImpact Healthcare Systems, Inc.

MedImpact Healthcare Systems, Inc. is the nation's largest full-service PBM that derives revenue by managing the drug benefit, not from dispensing drugs. We use information technology and human capital to improve the practice of managed care pharmacy. MedImpact partners with the nation's finest health plans, hospitals and employers to provide pharmacy benefit management services to more than 35 million members.

Read the original post:
MedImpact Healthcare Systems Expands Scope of Specialty Pharmacy Solutions